Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 13/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 11/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525664 | 0.83 | NPC1 (0.60) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL7521744 | 0.83 | RAB9A (0.50) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL7522955 | 0.81 | KDM4E (0.55) | MEN1KMT2ARAB9ANPC1LMNA | |
| SCHEMBL7518729 | 0.81 | HTT (0.50) | HTTMEN1KMT2AGAAMAPT | |
| SCHEMBL27548140 | 0.80 | POLB (0.53) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL7519247 | 0.79 | SMN1; SMN2 (0.55) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL7519777 | 0.78 | MEN1 (0.54) | MEN1KMT2ALMNACXCR2MAPT | |
| SCHEMBL7521044 | 0.78 | GAA (0.49) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL13235126 | 0.78 | HTT (0.81) | HTTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL7514378 | 0.77 | MAOA (0.51) | HTTMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | ROCHE DIAGNOSTICS GMBH | 2002-05-16 | — | — | US | disclosed |
| US-6333346-B1 | AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| CN-1278256-A | Ureido and thioureido derivatives of 4-amino-2-(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | ROCHE DIAGNOSTICS GMBH (DE) | 2000-12-27 | — | — | CN | disclosed |
| EP-1009747-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012917-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | UTS2R, SRD5A2, SRD5A1 | HTT 3260/4885MEN1 3390/4885KMT2A 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.